scholarly journals Diet and Nutrients in Gastrointestinal Chronic Diseases

Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2693
Author(s):  
Antonio Corsello ◽  
Daniela Pugliese ◽  
Antonio Gasbarrini ◽  
Alessandro Armuzzi
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Eating Habits ◽  
Gastrointestinal Diseases ◽  
Daily Amount ◽  
Progression Of Disease ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
The Impact ◽  
Therapeutic Possibilities

Diet and nutrition are known to play key roles in many chronic gastrointestinal diseases, regarding both pathogenesis and therapeutic possibilities. A strong correlation between symptomatology, disease activity and eating habits has been observed in many common diseases, both organic and functional, such as inflammatory bowel disease and irritable bowel syndrome. New different dietary approaches have been evaluated in order improve patients’ symptoms, modulating the type of sugars ingested, the daily amount of fats or the kind of metabolites produced in gut. Even if many clinical studies have been conducted to fully understand the impact of nutrition on the progression of disease, more studies are needed to test the most promising approaches for different diseases, in order to define useful guidelines for patients.

Nutrition in gastrointestinal diseases

2020 ◽  
pp. 621-678
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Small Intestine ◽  
Coeliac Disease ◽  
Bowel Disease ◽  
Lactose Intolerance ◽  
Gastrointestinal Diseases ◽  
Inflammatory Bowel ◽  
Irritable Bowel

Mouth, Dental, Oesophageal, Stomach, Gastrectomy, Small intestine, Malabsorption, Steatorrhoea, Lactose intolerance, Inflammatory bowel disease, Coeliac disease, Fistulae, stoma, transplantation, Irritable bowel syndrome, colon, Gallbladder

Pathophysiological roles of proteases in gastrointestinal disease

2016 ◽  
Vol 310 (4) ◽  
pp. G234-G239 ◽  
Author(s):  
Laura E. Edgington-Mitchell
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Protease Activity ◽  
Current Knowledge ◽  
Gastrointestinal Disease ◽  
Gastrointestinal Diseases ◽  
Inflammatory Bowel ◽  
Substrate Cleavage ◽  
Irritable Bowel

Gastrointestinal diseases, such as irritable bowel syndrome, inflammatory bowel disease, and colorectal cancer, affect a large proportion of the population and are associated with many unpleasant symptoms. Although the causes of these diseases remain largely unknown, there is increasing evidence to suggest that dysregulated protease activity may be a contributing factor. Proteases are enzymes that cleave other proteins, and their activity is normally very tightly regulated. During disease, however, the balance between proteases and their inhibitors is often shifted, leading to altered spatial and temporal control of substrate cleavage. Evaluating protease levels in normal physiology and disease has relied heavily on the use of chemical tools. Although these tools have greatly advanced the field, they are not without caveats. This review provides an introduction to these tools, their application in the gut, and a summary of the current knowledge on the contribution of protease activity to gastrointestinal disease.

scholarly journals Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome

2018 ◽  
Vol 10 (472) ◽  
pp. eaap8914 ◽  
Author(s):  
Arnau Vich Vila ◽  
Floris Imhann ◽  
Valerie Collij ◽  
Soesma A. Jankipersadsing ◽  
Thomas Gurry ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Bowel Disease ◽  
Gastrointestinal Diseases ◽  
Control Analysis ◽  
Microbiota Composition ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Gut Microbiota Composition

Changes in the gut microbiota have been associated with two of the most common gastrointestinal diseases, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Here, we performed a case-control analysis using shotgun metagenomic sequencing of stool samples from 1792 individuals with IBD and IBS compared with control individuals in the general population. Despite substantial overlap between the gut microbiome of patients with IBD and IBS compared with control individuals, we were able to use gut microbiota composition differences to distinguish patients with IBD from those with IBS. By combining species-level profiles and strain-level profiles with bacterial growth rates, metabolic functions, antibiotic resistance, and virulence factor analyses, we identified key bacterial species that may be involved in two common gastrointestinal diseases.

scholarly journals Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Martina Ledergerber ◽  
◽  
Brian M. Lang ◽  
Henriette Heinrich ◽  
Luc Biedermann ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Single Nucleotide Polymorphisms ◽  
Bowel Disease ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
The Impact

Abstract Background Abdominal pain is a frequent symptom in patients with inflammatory bowel disease (IBD) including Crohn’s disease (CD) and ulcerative colitis (UC). Pain can result from ongoing inflammation or functional disorders imitating irritable bowel syndrome (IBS). Several single-nucleotide polymorphisms (SNPs) have been associated with IBS. However, the impact of IBS genetics on the clinical course of IBD, especially pain levels of patients remains unclear. Methods Data of 857 UC and 1206 CD patients from the Swiss IBD Cohort Study were analysed. We tested the association of the maximum of the abdominal pain item of disease activity indices in UC and CD over the study period with 16 IBS-associated SNPs, using multivariate ANOVA models. Results In UC patients, the SNPs rs1042713 (located on the ADRB2 gene) and rs4663866 (close to the HES6 gene) were associated with higher abdominal pain levels (P = 0.044; P = 0.037, respectively). Abdominal pain was not associated with any markers of patient management in a model adjusted for confounders. In CD patients, higher levels of abdominal pain correlated with the number of physician contacts (P < 10–15), examinations (P < 10–12), medical therapies (P = 0.023) and weeks of hospitalisation (P = 0.0013) in a multivariate model. Conclusions We detected an association between maximal abdominal pain in UC patients and two IBS-associated SNPs. Abdominal pain levels had a pronounced impact on diagnostic and therapeutic procedures in CD but not in UC patients.

Sign in / Sign up

Export Citation Format

Share Document